Nectintx
nectintx.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
aMoon
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
aMoon Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Discover the future of molecular glues with Coltac Therapeutics. Using a cutting-edge bacteria-based positive selection screening system…
AltruBio. Developing safer, more durable treatments to improve the lives of patients.
Lever Bio aims to translate groundbreaking discoveries in immuno-oncology into next-generation cancer immunotherapies.
Innovating Digital Healthcare for a Better Tomorrow. Founded in 2023, BELL Therapeutics applies original biotechnology and advanced…
Transforming Treatment in Immunology. Living at the crossroads of precision medicine and AI, Scipher Medicine is a precision immunology…
Difficult protein production made simple. A next-generation expression system for next-generation therapeutics.
Overview
NectinTX develops next-generation delivery platforms for immuno-oncology and precision therapeutics. Discover breakthrough protein expression technologies that power safer, more effective treatments.
News
Nectin Therapeutics has been honored with the esteemed European Innovation Council (EIC) Accelerator funding.
Among 1083 proposals, Nectin emerged as one of the 42 recipients of EIC funding, highlighting the promise of its groundbreaking cancer immunotherapy pipeline. Nectin has received an initial grant of €2.5M and stands to potentially secure up to €15M in equ
Read more
Report
Nectin expands Phase I trial of NTX1088 combination to global sites
Nectin Therapeutics has expanded its Phase I trial of NTX1088 to further four international sites, including two study centres in Israel.
Read more
Report
Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel
/PRNewswire/ -- Nectin Therapeutics Ltd., (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved...
Read more
Report
Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent
/PRNewswire/ -- Nectin Therapeutics Ltd., (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved...
Read more
Report
Nectin's Keytruda combo could fill gaps in immuno-oncology's treatment paradigm
The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.
Read more
Report
Merck and Nectin to Study Novel Anti-PVR Candidate with Keytruda
Merck and Nectin Therapeutics announced a research collaboration agreement to study the safety and efficacy of Nectin's investigational antibody in locally advanced and metastatic solid tumors.
Read more
Report
Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors
The first-in-human trial of NTX1088, a monoclonal antibody, will test its activity in patients who miss out on anti-PD-1 immunotherapy benefit.
Read more
Report
Nectin doses first subject in Phase I solid tumour immunotherapy trial
Nectin Therapeutics has dosed the first subject in a Phase I trial of NTX1088 in locally advanced and metastatic solid tumour patients.
Read more
Report
Nectin's Series A Hits $25M as Investors Support New Target for Solid Tumors
Nectin Therapeutics announced dosing of the first solid tumor patient in a Phase I clinical trial while additional investors jumped in to expand the company's Series A to just over $25 million.
Read more
Report
aMoon Fund Leads Investment Round
aMoon fund leads investment round in Nectin Therapeutics with initial closing of $6m, total investment expected to reach $15m Nectin will use the funding for further development of its next-generation immuno-oncology antibodies that help the immune system
Read more
Report